Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Study on conflict between capacity to pay and need for health care

Cardiovascular disease (CVD) in all its forms is the biggest cause of death across Europe. Although there is little doubt that better focus on prevention can lessen its impact, we are left with a series of fundamental questions to what extent can the impact be reduced, and at what cost. And are the health benefits of prevention worth the investment. The EUROASPIRE III health economics study aims to find out.

31 Aug 2010

Nutritional recommendations for management of sarcopenia published

Nutritional recommendations for the management of sarcopenia -- also described as age-related muscle and functional loss -- were published this past week in the clinical publication, Journal of American Medical Directors Association.

31 Aug 2010

ECG-based screening for young footballers at risk of heart disease needs to be reviewed: Study

The screening process for young footballers at risk of heart disease needs to be re-evaluated. That is the conclusion of a recent study, which has shown that the common criteria used for assessment does not take into account the type and intensity of the exercise performed. The single most common cause of sudden death in competitive footballers is hypertrophic cardiomyopathy - a disease that thickens the heart muscle without any obvious cause.

31 Aug 2010

International Symposium to explore Hybrid approach for congenital heart disease

Interventional cardiologists and cardiothoracic surgeons throughout the United States and the world, who treat patients with congenital heart disease, will gather at the Hilton Columbus at Easton Town Center August 31-September 2, 2010 for the International Symposium on the Hybrid Approach to Congenital Heart Disease (ISHAC).

31 Aug 2010

Data monitoring committee recommends early termination following impressive results of AVERROES study

The data monitoring committee of the AVERROES study, seeing overwhelming evidence of the success of apixaban in the prevention of stroke in patients with atrial fibrillation who are unsuitable for the conventional treatment of warfarin, has recommended early termination of this study. The decision came after repeated review and careful consideration of all efficacy and safety data.

31 Aug 2010

Increasing trend seen in hospital admissions due to atrial fibrillation

A growing epidemic of the world's most common heart rhythm disorder is resulting in an alarming number of hospital admissions in Australia, according to cardiology researchers.

31 Aug 2010

Peripheral arterial disease increases cardiovascular disease risk: Study

Most patients don't suspect a thing, and yet they are seriously ill: hardening of the arteries - peripheral arterial disease PAD - doubles the risk of premature death and serious cardiovascular events such as heart attack and stroke.

31 Aug 2010

Hospital admissions in Australia due to atrial fibrillation triples

A growing epidemic of the world's most common heart rhythm disorder is resulting in an alarming number of hospital admissions in Australia, according to cardiology researchers.

31 Aug 2010

Amsterdam Molecular first half 2010 net loss in line with last year

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the first half year of 2010.

31 Aug 2010

Patients with atherothrombosis are at increased risk of ischemic events: Study

Clinical descriptors can assist clinicians in identifying patients with various stages of atherothrombosis (abnormal fatty deposits in an artery) who are at high-risk of future cardiovascular events, according to a study that will appear in the September 22 issue of JAMA. The study is being released early online to coincide with its presentation at the European Society of Cardiology meeting in Stockholm.

30 Aug 2010

Genzyme responds to Sanofi-Aventis' unsolicited acquisition proposal

Genzyme Corp. today confirmed that it has received an unsolicited, non-binding proposal from Sanofi-Aventis to acquire all the outstanding shares of Genzyme for $69 per share in cash. The Genzyme board of directors met last night, unanimously affirmed its previous rejection of Sanofi's proposal, and instructed the company to send Sanofi the following response letter:

30 Aug 2010

MedCath to sell interest in Avera Heart Hospital of South Dakota to Avera McKennan

MedCath Corporation announced today it has entered into a definitive agreement to sell its subsidiary which is the indirect owner of a one-third ownership interest and management rights in Avera Heart Hospital of South Dakota to Avera McKennan. The transaction is expected to close in 45 to 90 days, subject to certain closing conditions.

30 Aug 2010

Latest achievements in brain research and treatment for mental disorders

Mental disorders, such as depression, anxiety disorders, addiction and schizophrenia are the core challenge of most health care systems around the world. In the EU alone, each year 27% of the total adult population - this corresponds to 83 Million citizens - suffer from mental disorders. Depression alone affects almost 20 million ranking in the EU as the most disabling disorder of all diseases.

30 Aug 2010

Jefferson scientists receive grant to study genetics of platelet gene expression

Scientists at Jefferson Medical College have received a four-year, $3 million National Institutes of Health grant funded by the National Heart, Lung and Blood Institute to study variations of platelet function, specifically, the genetics of platelet gene expression. The study aims to find data that can be translated into novel therapeutic strategies and develop better predictors of cardiovascular disease.

30 Aug 2010

Study finds BMI, thrombogenic factor increases cardiovascular risk

Although having a high body mass index (BMI) is a known risk factor for cardiovascular disease, researchers are only beginning to understand how BMI affects the physiological processes involved in the development of the disease. Now, a study of a subset of women in the Kronos Early Estrogen Prevention Study (KEEPS), suggests that as BMI increases, so do platelet reactivity and thrombogenic microvesicles and activated protein C in the blood-all of which contribute to the formation of atherothrombosis and associated cardiovascular events.

30 Aug 2010

David Mosser to discuss primary duty of macrophages at American Physiological Society conference

The term "macrophage" conjures images of a hungry white blood cell gobbling invading bacteria. However, macrophages do much more than that. Not only do they act as antimicrobial warriors, they also play critical roles in immune regulation and wound-healing. They can respond to a variety of cellular signals and change their physiology in response to local cues.

27 Aug 2010

Research: Impact of seafood components on human health

Seafood has an enormous potential to promote health. At the same time the opportunities for innovation and value creation are huge. Knowledge and documentation are the keys to success.

27 Aug 2010

Athera Biotechnologies, Electra-Box Diagnostica sign distribution agreement for 'CVDefine' kit

Athera Biotechnologies and Electra-Box Diagnostica, announced today that they have signed an agreement for distribution of "CVDefine" kit. CVDefine measures a new biomarker in blood, a specific anti-body, that has been linked to increased risk for cardiovascular disease. Athera Biotechnologies is part of the Karolinska Development portfolio.

27 Aug 2010

Second-hand smoke triggers complex inflammatory response

Second-hand smoke is associated with a number of diseases and conditions, including cancer, heart disease, and emphysema. It is an irritant to lung tissue and blood vessels, but the processes through which the body reacts to second-hand smoke comprise a mystery scientists are only beginning to unravel. Researchers at the University of Colorado-Denver are currently studying how second-hand smoke affects the lungs of rats, and so far it appears that second-hand smoke triggers a complex inflammatory response.

27 Aug 2010

New York State permits Genelex Corporation's DNA Drug Sensitivity Tests

The New York State Department of Health has licensed Genelex Corporation's DNA Drug Sensitivity Tests for use by doctors in the state. The issued Clinical Laboratory Permit is for DNA testing of three enzymes, the cytochrome P450s, that process more than 50 percent of the most commonly prescribed medicines.

27 Aug 2010